Budapest’s Semmelweis University is testing the effectiveness of a new experimental oral antiviral drug for patients who have contracted the COVID-19 virus.
Semmelweis University joined an international trial on August 23rd and was the first in the European Union to conduct a clinical trial under the program, and the second in the EU to have the product administered.
The approval and administrative procedures for the trial were completed in record time at the institutional level, the university revealed in …
Ugras az eredeti oldalra
First Experimental COVID-19 Drug Administered in Hungary
Powered by WPeMatico